Park Jae Jun, Yang Suk-Kyun, Ye Byong Duk, Kim Jong Wook, Park Dong Il, Yoon Hyuk, Im Jong Pil, Lee Kang Moon, Yoon Sang Nam, Lee Heeyoung
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Intest Res. 2017 Jan;15(1):38-67. doi: 10.5217/ir.2017.15.1.38. Epub 2017 Jan 31.
Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.
克罗恩病(CD)是一种慢性、进行性且致残的炎症性肠病(IBD),其病因发病机制尚不明确。CD可累及从口腔到肛门的胃肠道任何部位,并伴有严重并发症,如肠狭窄、穿孔和瘘管形成。韩国CD的发病率和患病率与西方国家相比仍然较低,但在最近几十年中一直在迅速上升。虽然目前尚无针对CD的确切治愈方法,但已应用各种药物和手术疗法来治疗这种疾病。在CD的管理方面,临床医生之间根据个人经验和偏好存在很大差异。为了针对CD的各种问题提出可推荐的方法,并尽量减少医生之间治疗的差异,韩国肠道疾病研究协会IBD研究组于2012年首次发布了CD管理指南。这些是基于2012年以来积累的最新证据修订的指南。这些指南主要采用改编方法制定,涵盖CD的诱导和维持治疗、基于疾病部位的治疗、CD并发症(包括狭窄和瘘管)的治疗、手术治疗以及术后复发的预防。这些是韩国第二部CD管理指南,并将随着新证据的收集不断修订。